Insights into addressing the gap between biological activity and clinical outcomes in preclinical inflammatory disease research.
Many compounds demonstrate compelling activity in preclinical inflammation models, with clear modulation of cytokine profiles, immune cell infiltration, and tissue pathology. Yet, these same compounds don’t always fulfil clinical expectations. This disconnect highlights a familiar challenge: what defines preclinical success is not always what determines success in patients.
The role of biomarkers in preclinical research
Biomarkers sit at the center of preclinical research for a good reason. Histological assessments, cytokine profiling, and immune phenotyping provide critical evidence of biological activity. They enable confirmation of target engagement, help elucidate mechanism of action, and support early proof of concept. Without them, it would be difficult to understand whether a compound is interacting with the intended pathway or producing a measurable effect at all. In this sense, biomarkers remain foundational to preclinical development.
However, in inflammatory disease research, clinical success is rarely defined by changes in biomarkers alone. In patients, outcomes are assessed through functional improvement: reduction in symptoms, restoration of organ function, and overall impact on quality of life. In inflammatory skin diseases, this may mean reducing itch. In lung diseases, it may involve preserving or improving breathing capacity. These are not indirect measures of biology, but direct reflections of disease burden.
Where biomarkers fall short
The challenge is that improvements in biomarkers do not always translate into these functional outcomes. A compound may reduce inflammatory signals or normalize tissue structure, yet still fail to meaningfully improve how a patient feels or functions. When preclinical evaluation relies solely on biomarker data, there is a risk of overestimating therapeutic impact and advancing programs without a full understanding of how they will be assessed in the clinic.
This is where functional and behavioral readouts become much more important. By incorporating endpoints that reflect patient-relevant outcomes, preclinical studies can better align with what will ultimately be measured by clinicians. Readouts such as scratching behavior in models of atopic dermatitis or lung function in models of pulmonary fibrosis provide an additional layer of insight for these diseases that complements biomarker data rather than replacing it. In some cases, these measures can reveal limitations in efficacy that would not be apparent from biological markers alone.
A more complete view of efficacy
A more complete view of efficacy therefore comes from combining both approaches. Biomarkers answer whether a biological process has been modulated. Functional readouts help determine whether that modulation translates into a meaningful effect on patient symptoms and disease burden. Together, they provide a more robust basis for decision-making, strengthening confidence in the data and its relevance to clinical outcomes.
For teams designing preclinical programs, this has practical implications. Integrating functional endpoints, particularly at later stages of evaluation, can help reduce uncertainty and support more informed progression decisions. It also encourages a closer alignment between study design and clinical expectations, which is increasingly important in a competitive and resource-constrained development landscape.
Biomarkers remain essential. However, on their own, they provide only part of the picture when studying inflammatory diseases. Incorporating functional readouts offers a way to better capture what ultimately matters: not just whether the biology changes, but whether that change makes a difference to the patient.
If you would like to know more about how we support inflammatory disease research, including functional and biomarker readouts, pleased get in touch with our team today.
Alternatively, you can register for our upcoming free webinar on integrating functional studies into preclinical inflammatory disease research (details below).
